NASDAQ:ENVB Enveric Biosciences (ENVB) Stock Price, News & Analysis $1.46 -0.06 (-3.96%) As of 03:56 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About Enveric Biosciences Stock (NASDAQ:ENVB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Enveric Biosciences alerts:Sign Up Key Stats Today's Range$1.45▼$1.5450-Day Range$1.37▼$1.6252-Week Range$1.17▼$13.25Volume31,355 shsAverage Volume1.24 million shsMarket Capitalization$6.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Enveric Biosciences is a biotechnology company developing small-molecule treatments for mental health conditions. Its research focuses on neuroplastogens—compounds designed to promote changes in neural connections—with potential applications in disorders such as depression and anxiety. The company uses its Psybrary platform, a library of compounds inspired by psychedelic molecules, to identify and develop therapeutic candidates. Its programs are in development, and the company’s work is focused on research rather than marketed medicines. Enveric expanded into psychedelic-inspired drug discovery through its 2021 acquisition of MagicMed Industries. It is headquartered in Naples, Florida.AI Generated. May Contain Errors. Read More Enveric Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreENVB MarketRank™: 1.3480911983 of 5 starsEnveric Biosciences scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingEnveric Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEnveric Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Enveric Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Enveric Biosciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enveric Biosciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnveric Biosciences has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.45% of the float of Enveric Biosciences has been sold short.Short Interest Ratio / Days to CoverEnveric Biosciences has a short interest ratio ("days to cover") of 0.56, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enveric Biosciences has recently decreased by 49.31%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnveric Biosciences does not currently pay a dividend.Dividend GrowthEnveric Biosciences does not have a long track record of dividend growth. News and Social Media4.4 / 5News Sentiment0.98 News SentimentEnveric Biosciences has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Enveric Biosciences this week, compared to 2 articles on an average week.Search Interest1 people have searched for ENVB on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Enveric Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enveric Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders2.41% of the stock of Enveric Biosciences is held by insiders.Percentage Held by Institutions13.82% of the stock of Enveric Biosciences is held by institutions.Read more about Enveric Biosciences' insider trading history. Receive ENVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENVB Stock News HeadlinesEnveric Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 14 at 2:18 PM | marketscreener.comMEnveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate UpdateNovember 13 at 5:00 PM | businesswire.comBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years.November 16 at 1:00 AM | Paradigm Press (Ad)Enveric Biosciences reports favorable brain activity data for lead psychiatric drug candidateNovember 4, 2026 | msn.comEnveric Biosciences Moves Lead Neuroplastogenic Candidate Closer To Clinical TestingOctober 22, 2026 | rttnews.comEnveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET StudiesOctober 21, 2026 | marketscreener.comMEnveric Biosciences Inc ENVBSeptember 16, 2026 | morningstar.comMEnveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 SeriesSeptember 15, 2026 | finance.yahoo.comSee More Headlines ENVB Stock Analysis - Frequently Asked Questions How have ENVB shares performed this year? Enveric Biosciences' stock was trading at $3.63 on January 1st, 2026. Since then, ENVB stock has decreased by 59.9% and is now trading at $1.4550. How were Enveric Biosciences' earnings last quarter? Enveric Biosciences, Inc. (NASDAQ:ENVB) issued its quarterly earnings results on Friday, November, 13th. The company reported ($0.57) EPS for the quarter. When did Enveric Biosciences' stock split? Enveric Biosciences shares reverse split on the morning of Wednesday, January 29th 2025.The 1-15 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Enveric Biosciences' major shareholders? Top institutional investors of Enveric Biosciences include StoneX Group Inc. (0.63%). View institutional ownership trends. How do I buy shares of Enveric Biosciences? Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enveric Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enveric Biosciences investors own include Palantir Technologies (PLTR), MARA (MARA), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), Tesla (TSLA), AMC Entertainment (AMC) and IonQ (IONQ). Company Calendar Last Earnings11/13/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ENVB's financial health is in the Yellow zone, according to TradeSmith. ENVB has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ENVB CIK890821 Webwww.enveric.com Phone(617) 444-8400Fax732-243-9254Employees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)($12.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-162.87% Return on Assets-144.23% Debt Debt-to-Equity RatioN/A Current Ratio10.21 Quick Ratio10.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.00 per share Price / Book0.21Miscellaneous Outstanding Shares4,476,000Free Float4,368,000Market Cap$6.58 million OptionableNot Optionable Beta1.23 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ENVB) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges inves...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enveric Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.